SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (567)11/4/2003 11:27:25 AM
From: Icebrg  Read Replies (1) | Respond to of 1022
 
NovImmune is a Medarex collaborator.
Erik

PRINCETON, N.J. and GENEVA, Switzerland, May 17 [2001] /PRNewswire/ --
Medarex, Inc. (Nasdaq: MEDX) and NovImmune SA today announced a collaboration for the development of fully human therapeutic antibodies. Medarex expects to use its UltiMAb(TM) Human Antibody Development System(SM) to generate antibodies to disease targets discovered by NovImmune.